Good Pharmaceutical Development Company

Good Pharmaceutical Development Company (GPDC) is a biotechnology firm that specializes in the development of cannabinoid-based therapeutic products for pain management and infectious diseases. Founded by gastroenterologist Dr. Larry Good, the company is best known for its lead product, Remei (formerly PainTx), a high-concentration topical CBD cream designed to treat acute and chronic pain without systemic absorption. GPDC utilizes a proprietary delivery system to ensure effective local delivery of cannabinoids to affected tissues. Additionally, the company has collaborated with the University of Lethbridge to develop a cannabis-based oral rinse aimed at reducing the severity and duration of COVID-19 by targeting ACE2 receptors. Although the company was active in clinical research and commercialization of CBD products, recent reports indicate it has ceased operations as of early 2026.